Ingenus Pharms Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INGENUS PHARMS LLC, and what generic alternatives to INGENUS PHARMS LLC drugs are available?
INGENUS PHARMS LLC has ten approved drugs.
There is one US patent protecting INGENUS PHARMS LLC drugs. There is one tentative approval on INGENUS PHARMS LLC drugs.
There is one patent family member on INGENUS PHARMS LLC drugs in one country and fifteen supplementary protection certificates in seven countries.
Summary for Ingenus Pharms Llc
| International Patents: | 1 |
| US Patents: | 1 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
Drugs and US Patents for Ingenus Pharms Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingenus Pharms Llc | CABERGOLINE | cabergoline | TABLET;ORAL | 204735-001 | Aug 1, 2018 | AB | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ingenus Pharms Llc | TIMOLOL MALEATE | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 216533-002 | Sep 13, 2022 | AT3 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Ingenus Pharms Llc | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 212501-003 | Nov 19, 2021 | RX | Yes | Yes | 10,993,952 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ingenus Pharms Llc | CYCLOPHOSPHAMIDE | cyclophosphamide | SOLUTION;INTRAVENOUS | 212501-001 | Jul 30, 2020 | RX | Yes | Yes | 10,993,952 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Ingenus Pharms Llc | IVABRADINE HYDROCHLORIDE | ivabradine hydrochloride | TABLET;ORAL | 214051-002 | Dec 30, 2021 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Ingenus Pharms Llc | ARSENIC TRIOXIDE | arsenic trioxide | INJECTABLE;INJECTION | 209315-001 | Nov 15, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ingenus Pharms Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016132270 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ingenus Pharms Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2701720 | 3/2023 | Austria | ⤷ Try a Trial | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
| 0509752 | SPC/GB99/043 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 |
| 0509752 | 49/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306 |
| 2701720 | 301206 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
| 2701720 | CR 2022 00054 | Denmark | ⤷ Try a Trial | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
| 0166287 | SPC/GB96/056 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: PANTOPRAZOLE AND ITS SALTS, HYDRATES AND HYDRATES OF ITS SALTS; REGISTERED: SE SE12131 19940506; UK 04889/0010 19960604 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
